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ABSTRACT
HIV-1 requires the CD4 receptor and a coreceptor (CCR5 [R5 phenotype] or CXCR4 [X4 phenotype]) to enter cells. Coreceptor
tropism can be assessed by either phenotypic or genotypic analysis, the latter using bioinformatics algorithms to predict tropism
based on the envV3 sequence. We used the Primer ID sequencing strategy with theMiSeq sequencing platform to reveal the
structure of viral populations in the V1/V2 and C2/V3 regions of the HIV-1 env gene in 30 late-stage and 6 early-stage subjects.
We also used endpoint dilution PCR followed by cloning of env genes to create pseudotyped virus to explore the link between
genotypic predictions and phenotypic assessment of coreceptor usage. We found out that the most stringently sequence-based
calls of X4 variants (Geno2Pheno false-positive rate [FPR] of<2%) formed distinct lineages within the viral population, and
these were detected in 24 of 30 late-stage samples (80%), which was significantly higher than what has been seen previously by
using other approaches. Non-X4 lineages were not skewed toward lower FPR scores in X4-containing populations. Phenotypic
assays showed that variants with an intermediate FPR (2 to 20%) could be either X4/dual-tropic or R5 variants, although the X4
variants made up only about 25% of the lineages with an FPR of<10%, and these variants carried a distinctive sequence change.
Phylogenetic analysis of both the V1/V2 and C2/V3 regions showed evidence of recombination within but very little recombina-
tion between the X4 and R5 lineages, suggesting that these populations are genetically isolated.
IMPORTANCE
Primer ID sequencing provides a novel approach to study genetic structures of viral populations. X4 variants may be more prev-
alent than previously reported when assessed by using next-generation sequencing (NGS) and with a greater depth of sampling
than single-genome amplification (SGA). Phylogenetic analysis to identify lineages of sequences with intermediate FPR values
may provide additional information for accurately predicting X4 variants by using V3 sequences. Limited recombination occurs
between X4 and R5 lineages, suggesting that X4 and R5 variants are genetically isolated andmay be replicating in different cell
types or that X4/R5 recombinants have reduced fitness.
Human immunodeficiency virus type 1 (HIV-1) requires theCD4 receptor and a coreceptor to infect host cells. Entry is
mediated by the viral envelope protein (Env), which is processed
to give two associated subunits, gp120 and gp41, that assemble
into a trimeric structure embedded in the viral envelope/mem-
brane. The binding of gp120 to CD4 triggers a structural change
that exposes its variable region 3 (V3) loop, which is part of the
coreceptor domain (1, 2). The majority of transmitted/founder
(T/F) viruses and viruses isolated from the clinically latent stage in
HIV-infected subjects use CCR5 as the coreceptor, making the
virus CCR5 tropic (or an R5 virus). The virus can evolve to use
CXCR4 (CXCR4 tropic [or an X4 virus]), and viruses that have
switched coreceptor usage are found mostly in late-stage subjects
with low CD4 T cell counts (3, 4). Viruses evolving an X4 phe-
notype often retain some capacity to use CCR5 for entry and are
often referred to as X4/dual-tropic viruses.
Coreceptor tropism can be assessed by either phenotypic or
genotypic analysis. Cell-based assays for entry phenotype test ei-
ther virus isolates or viruses pseudotyped by using cloned viral env
genes. Phenotyping consists of infecting cells expressing CD4 and
either CCR5 or CXCR4 (5, 6) or inhibiting infection with antag-
onists of CCR5 and/or CXCR4. Alternatively, assignment of core-
ceptor tropismby sequence analysis has been based on sequencing
of the V3 loop coding domain of the viral env gene. As the V3 loop
of gp120 directly interacts with the coreceptor, the sequence of the
V3 loop is the major determinant of the coreceptor tropism phe-
notype (7, 8). In contrast to V3, which appears to be variable due
to the coreceptor switch, variable regions V1, V2, V4, and V5 are
surface loops of the gp120 subunit involved in autologous anti-
body escape, and these regions are separated by relatively constant
regions (i.e., C1, V1/V2, C2, V3, C4, V4, C5, V5, and C6).
Several bioinformatics interpretation systems have been devel-
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oped to assess V3 sequence data to infer coreceptor tropism. The
11/25 charge rule is the simplest algorithm based on the presence
of basic amino acids at positions 11 and/or 25 of the V3 loop
(positions 1 and 35 are invariant cysteines that form a disulfide
bond with each other, creating the intervening loop). However,
the 11/25 rule lacks sensitivity in detecting X4 variants compared
with phenotypic assays (9), with an Arg residue at position 25
being the least predictive. The position-specific scoring matrix
(PSSM) analyzes the entire V3 sequence and predicts X4 variants
based on a scoring of the probability of the amino acid at each
position being overrepresented among X4 sequences versus R5
sequences (10). The Geno2Pheno (G2P) algorithm (11) also ana-
lyzes the entire V3 sequence and provides a quantitative score
(false-positive rate [FPR]) representing the probability of falsely
predicting an R5 variant as an X4 variant; the validity of this ap-
proach has been assessed in several clinical trials (12–16). G2P has
been widely used in research and clinical settings, but it requires a
preset FPR cutoff to call X4 variants. There is significant uncer-
tainty aboutwhere to place the FPR cutoff and about the reliability
of the FPR values in the intermediate range as representing the
frequency of X4 and R5 variants with those intermediate FPR
values, creating uncertainty about overcalls and undercalls, espe-
cially in the context of X4 evolution and coexisting viral lineages.
HIV-1 displays extensive genetic diversity and undergoes rapid
evolution within individual hosts (17), and the env gene has the
most sequence diversity of all of the HIV-1 genes, which can often
include coexisting distinct lineages within a person.However, cer-
tain approaches to the analysis of env genes can confound the
interpretation due to the introduction of artifacts into the data set.
Bulk PCR amplification of a population of sequences can lead to
PCR-mediated recombination, which significantly affects the
quality of the phylogenetic analysis (18). Endpoint dilution PCR
(EPD PCR) (also called single-genome amplification [SGA] or
single-genome sequencing [SGS]) combined with Sanger se-
quencing avoids the confounding effect of PCR-mediated recom-
bination and allows a true assessment of viral sequences as they
appear in the viral population (18, 19). EPDPCR is time-consum-
ing and labor-intensive, making it challenging to analyze more
than a few dozen viral genomes per sample (20–22), which limits
the depth of sampling of viral genomes when assessing the com-
plexity of the viral population. Recently, viral population studies
have started to incorporate deep-sequencing or next-generation
sequencing (NGS) technologies that have the capacity to greatly
extend the depth of sampling (12, 23–28). However, conventional
approaches using NGS in HIV-1 population studies have serious
limitations in representing an accurate sampling of the original
viral population. Artifactual heterogeneity can be introduced due
to the preceding PCR step, which introduces misincorporation
and recombination (29, 30) as well as high rates of sequencing
errors associated with NGS, while artifactual homogeneity can be
introduced by PCR resampling of the same starting templates (31)
and using reference sequences to construct consensus sequences
for variable regions. We have overcome these limitations by using
the Primer ID sequencing approach to define template sampling
depth and reduce the error rate to around 1 in 10,000 nucleotides
(32, 33).
Here we present a study in which we used the Primer ID ap-
proach coupled with Illumina MiSeq paired-end sequencing to
reveal the structure of viral populations in the V1/V2 and C2/V3
regions of theHIV-1 env gene and to predict coreceptor tropism in
sequence lineages found in chronically infected and post-acute-
phase HIV-infected subjects. We also used EPD PCR followed by
cloning of env genes for use in pseudotyping to explore the link
between genotypic predictions and phenotypic assessment, focus-
ing on distinguishing intermediate prediction values. Neither of
these approaches (Primer ID NGS or EPD PCR) has been used to
examine the presence of X4 variants in samples taken from late-
stage subjects. We found that X4/dual-tropic variants form dis-
crete lineages within the viral population, typically having G2P
FPR scores of 2%. The coincident R5 populations in subjects
with X4/dual-tropic viruses present were not skewed toward X4-
like sequences compared to all-R5 populations or transmitted/
founder viruses. The X4 and R5 populations were genetically iso-
lated based on the inability to detect significant recombination
between the R5 and X4 populations when V1/V2 and V3 markers
were compared. Finally, we suggest sequence determinants of the
V3-associated entry phenotype that could explain some of the
uncertainty in making an R5 or X4 call associated with viruses
with intermediate FPR genotypic scores.
MATERIALS AND METHODS
Study participants and clinical samples. We examined 30 plasma sam-
ples from late-stage subjects (withCD4Tcell counts of100 cells/mm3)
and 6 plasma samples from early-stage subjects (within the first 2 years of
infection). All subjects were infected with subtype B HIV-1, and all sub-
jects provided informed consent to participate in protocols that were ap-
proved by the Institutional Review Boards (IRBs) at Yale University,
UCSF, andUNC. Late-stage sampleswere obtained at the entry time point
from subjects whowere enrolled in an early trial of ritonavir (34); some of
the subjects had had prior exposure to zidovudine (AZT) and/or lamivu-
dine (3TC) as monotherapy, and early-stage subjects were naive to anti-
retroviral therapy.
cDNA synthesis and MiSeq library construction. We used the
QIAamp viral RNA minikit (Qiagen, Valencia, CA) to extract viral RNA
from the plasma samples and a previously described approach to con-
struct the Primer ID MiSeq library after cDNA synthesis using the viral
RNA as the template and PCR (33). The Primer ID cDNA primer was
composed of the complement of the target region in the RNA template for
cDNA synthesis (HXB2 [GenBank accession number K03455] number-
ing for the gene-specific region spanning positions 7209 to 7238, at the 3=
boundary of the V3 coding region of the env gene), an 8-base random
sequence that served as the Primer ID and one random nucleotide as a
sequencing buffer, and a 5= tail of the primer sequence that served as the
PCR primer. The sequence of the cDNA primer was 5=-GTGACTGGAG
TTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNCAGTCCATTT
TGCTCTACTAATGTTACAATGTGC-3=. We ordered hand-mixing for
the synthesis of the Primer ID cDNA primer (IDT, Coralville, IA) to
maximize the randomness of the nine degenerate base positions. Super-
Script III reverse transcriptase (Life Technologies, Grand Island, NY) was
used for cDNA synthesis, with the chosen number of RNA templates
(typically between 5,000 and 10,000 copies of viral RNA per reaction)
being estimated based on viral load testing. After cDNA synthesis, all
samples were purified by using Agencourt RNAClean XP magnetic beads
(Beckman Coulter, Brea, CA) with a stringent wash protocol (the ratio of
the volume of beads to cDNA was 0.6 to 1.0, with the beads being washed
4 times) to remove unused cDNA primers. All of the purified cDNA was
used for the first of two rounds of PCR amplification. The first-round
forward and reverse PCR primers were 5=-GCCTCCCTCGCGCCATCA
GAGATGTGTATAAGAGACAGNNNNTTATGGGATCAAAGCCTAA
AGCCATGTGTA-3= (HXB2 numbering for the gene-specific region
spanning positions 6555 to 6584, just upstream of the V1/V2 region of the
env gene) and 5=-GTGACTGGAGTTCAGACGTGTGCTC-3=, respec-
tively. PCR products from the first-round PCR were purified by using
Agencourt AMPure XP PCRpurification beads (BeckmanCoulter) with a
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stringent protocol (the ratio of the volume of beads toDNAwas 0.6 to 0.8,
with the beads being washed 2 times). This step also allowed us to create
heterogeneity near the left end of the amplicon (the N4 stretch in the
primer) so that there was efficient cluster assignment during the sequenc-
ing step. We used the Illumina indexed primers as the second-round
reverse PCR primers to tag each sample with a unique bar code, allowing
us tomultiplex up to 24 libraries in the same sequencing run. The forward
and reverse primers for second-round PCR were 5=-AATGATACGG
CGACCACCGAGATCTACACGCCTCCCTCGCGCCATCAGAGAT
GTG-3= and 5=-CAAGCAGAAGACGGCATACGAGATNNNNNNGT
GACTGGAGTTCAGACGTGTGCTC-3=, respectively. The 6-nucleotide
stretch of N=s represents the position of the 24 Illumina bar codes. Kapa
Robust and Kapa High-Fidelity PCR kits (Kapa Biosystems, Woburn,
MA) were used for first- and second-round PCR amplification, respec-
tively. The second-round PCR products were gel purified by using a
QIAquick MinElute gel extraction kit (Qiagen). The recovered DNA was
then quantified by using aQubit 2.0 fluorometer (Life Technologies), and
the products were pooled in equal amounts. Library quality was assessed
by using the Experion electrophoresis system (Bio-Rad, Hercules, CA).
Illumina sequencing and bioinformatics pipelines. The UNC High
Throughput Sequencing Facility performed Illumina MiSeq analysis by
using either 250-nucleotide or 300-nucleotide paired-end sequencing. A
random PhiX genomic DNA library was mixed with the HIV-1 library
pool to increase the complexity between clusters on the flow cell. The
Illumina pipeline (v.1.8.2) was used to generate sequence reads with as-
signed quality scores. In-house bioinformatics pipelines written in Ruby
were used to filter out sequence reads of low quality, link sequence end
pairs, capture Primer IDs, and create consensus sequences without a ref-
erence sequence. To avoid the inclusion of sequencing errors in the
Primer ID sequence tag (offspring Primer IDs) that would create artifac-
tual viral genomes, we calculated a cutoff for the number of raw reads
needed for each Primer ID to form a template consensus sequence (TCS)
based on a simulation to estimate the frequency of offspring Primer IDs
with errors. We then used Primer IDs with a number of raw reads above
this cutoff to create a TCS for each starting RNA template (33). Addition-
ally, TCSs were filtered for large deletions and frameshifts.
EDPPCRandphenotypingof coreceptor usage. env gene cloneswere
generated as previously described (22). In brief, cDNA was generated by
using an oligo(dT) primer from viral RNA isolated from blood plasma,
followed by EDP PCR (3, 18, 35) to amplify full-length env genes for
sequencing. DNA sequence alignments of the env genes were performed
by using ClustalW (36). Sequences for each subject were codon aligned,
and phylogenetic trees were generated by using a neighbor-joining
method (MEGA5) (37). An additional round of amplification was per-
formed to reamplify env genes for the purpose of cloning into the pcDNA
3.1D/V5-His_TOPO expression vector (Life Technologies), and these
clones were used for pseudotype virus production.
293T cells were cultured in Dulbecco’s modified Eagle medium
(DMEM) with 4.5 g/liter glucose (Mediatech, Manassas, VA) supple-
mented with 10% fetal bovine serum (FBS), 50 U/ml penicillin, and 50
g/ml streptomycin. Affinofile cells (38) were also cultured inDMEMbut
supplemented with 10% dialyzed FBS (12- to 14-kDa cutoff; Atlanta Bi-
ologicals, Flowery Branch, GA) and 50 mg/ml blasticidin (Life Technolo-
gies).
Env-pseudotyped luciferase reporter viruses were generated by
cotransfection of 0.81 g of the pNL4-3.LucR-E plasmid (obtained from
the NIH AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH), 0.81 g of an HIV-1 env clone, and 4.9 l of Fu-
GENE6 transfection reagent (Promega,Madison,WI) in a total volumeof
75 l of medium added to 1 well of a 6-well dish seeded with 2.4  105
293T cells. At 5 h posttransfection, themediumwas replaced, and the cells
were incubated at 37°C for 36 to 42 h. Pseudotyped-virus stocks were
isolated from the supernatants by filtration though a 0.45-mfilter (Mil-
lipore, Billerica, MA) prior to storage at 80°C. Virus stocks were not
subjected to multiple freeze-thaw cycles.
Affinofile cell assays were performed as previously reported (38). In
short, Affinofile cells were plated into black poly-L-lysine (Sigma)-treated
96-well plates at a concentration of 1.8 104 cells/well. Cells were induced
for CCR5 andCD4 expression by using ponasteroneA (PonA) (Life Tech-
nologies) and doxycycline (Doxy) (Sigma, St. Louis, MO) for 24 h before
medium exchange and virus addition (Affinofile cells constitutively ex-
press CXCR4). Cells were centrifuged at 2,000 rpm for 2 h at 37°C in the
presence of virus to enhance infection (i.e., spinoculated), followed by
incubation for 48 h at 37°C, and then washed two times with phosphate-
buffered saline (PBS) prior to being lysed with 50 l of 1 reporter lysis
buffer (Promega) and stored at80°C. Viral entry was assessed using the
luciferase assay system (Promega) by thawing the lysates and quantifying
luciferase expression. Virus stocks were titrated by using Affinofile cells
expressing maximum levels of CD4 and CCR5. The amount of virus used
for an infectionwas determined by calculating the volume of virus needed
to produce 800,000 relative light units (RLU) of luciferase readout, a
value near the high endof the linear portion of the dose-response curve for
luciferase activity in our assay.
Coreceptor usage was determined by infecting cells in the presence of
maraviroc, AMD3100, or maraviroc plus AMD3100 (both obtained from
the NIH AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH). The coreceptor phenotype was determined by using
Affinofile cells expressing a single high level of CD4 (Doxy) and a high
level of CCR5 (PonA). One hour prior to spinoculation, the coreceptor
antagonist was added at a single high dose (50 M maraviroc, 2 M
AMD3100, or 50 Mmaraviroc plus 2 MAMD3100). After spinocula-
tion, themediumwas removed and replacedwith freshmedium, followed
by a 48-h incubation at 37°C. The cells were then washed with PBS, and
lysis buffer was added, followed by freezing, thawing, and then assaying
for luciferase activity.
Phylogenetic analysis and coreceptor tropism prediction. Full-
length env sequences derived from the EPD PCR amplicons from each
sample were trimmed to include the same region as that in the NGS
consensus sequences. We used MUSCLE (v3.8.1) (39, 40) to align se-
quencing reads and construct neighbor-joining trees for the V1/V2 region
and the C2/V3 region separately. Coreceptor genotyping of V3 sequences
from bothNGS and EPDPCRwas performed by using the G2P algorithm
(11) to generate an FPR value.
Nucleotide sequence accession numbers. RawMiSeq sequencing reads
are available at the NCBI Sequence Read Archive (SRA) (SRX1628641,
SRX1628643, SRX1628644, SRX1628655, SRX1628657–SRX1628660,
SRX1628663, SRX1628670, SRX1628675, SRX1628682, SRX1628688–
SRX1628690, SRX1628697, SRX1628704–SRX1628706, SRX1628709,
SRX1628719, SRX1628720, SRX1628722, SRX1628729, SRX1628731–
SRX1628736, SRX1628740, and SRX1628742–SRX1628746).
RESULTS
Development of anHIV-1 env gene amplicon for paired-end se-
quencing. Next-generation sequencing offers new opportunities
to examine the structure of genetically diverse populations, such
as HIV-1. However, different platforms offer different advantages
in read length, number of reads, and accuracy of reads. We have
developed an amplicon to examine HIV-1 env populations using
the MiSeq platform based on 250-nucleotide (now 300-nucleo-
tide) paired-end reads. We chose to generate an 835-bp amplicon
starting upstream of the V1 region (HBX2 position 6555) and
extending through the V3 region (HBX2 position 7238). In the
paired-end-read strategy, 200 to 250 nucleotides of HIV-spe-
cific sequence are generated from each end of the amplicon. This
allows 216 nucleotides of theV1/V2 region and all of theV3 region
and into C2 to be analyzed, and with the current 300-nucleotide
paired-end sequencing, the entire V1/V2 region can be captured
inmost cases. In the current format, these paired-end reads do not
overlap, although the MiSeq platform allows them to be linked as
Zhou et al.
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coming from the same templatemolecule.We targeted this region
for deep-sequencing analysis since the V1/V2 region is the most
diverse sequencewithin theHIV-1 genome, and theV3 region can
be used to infer the X4 or R5 entry phenotype for the virus.
cDNA synthesis was done by using a primer that included a
9-nucleotide stretch of randomized bases, an indexing strategy
that we have termed Primer ID (32, 33); the Primer ID cDNA
primer was used just for cDNA synthesis and then removed prior
to the PCR step. This allowed each RNA template to be linked to a
unique sequence tag that could be identified in a subsequent se-
quence analysis. The cDNA was then amplified by PCR using a
primer that was complementary to a region in the cDNA primer
that was behind the Primer ID sequence tag, with the other PCR
primer being a gene-specific upstream/forward primer. This ap-
proach largely resolves two significant limitations of the use of
NGS for a genetically diverse population that is first amplified by
PCR: it allows the recognition of PCR resampling, i.e., the repet-
itive sequencing of the original template sequences as represented
many times in the PCR product, which is identified by tagging
each template with a unique sequence tag, and it allows PCR re-
sampling (i.e., sequences with the same Primer ID sequence) to be
used to create a TCS for each original template to remove most of
the PCR and sequencing errors.
Characteristics of HIV-positive subjects providing plasma
samples for sequence analysis. Table 1 shows the characteristics
of the study subjects and the blood plasma samples provided as
well as the number of TCSs that we obtained for each plasma
sample. In this initial characterization of the V1-V3 env sequence
amplicon, we examined samples from 30 subjects late in the
course of their HIV-1 infection, as indicated by their low average
CD4 T cell counts (23 cells/l) and relatively high average viral
loads (5.2 log10 copies/ml) (Table 1). We also included samples
from six subjects early in infection with a median estimated num-
ber of days of infection of 328, a median CD4 T cell count of 600
cells/l, and amedian viral RNA load of 4.6 log10 copies/ml (Table
1). Ten of the late-stage and the six early-stage samples were se-
quenced by using the 250-nucleotide paired-end sequencing pro-
tocol in one library pool, and the other 20 late-stage samples were
sequenced by using the 300-nucleotide paired-end sequencing
protocol in a second pool. The median numbers of TCSs of late-
and early-stage subjects were 1,357 and 1,532, respectively, de-
rived frommedians of 557,450 and 170,310 raw reads, respectively
(Table 1); given the average number of reads per template in these
runs, the low-end read cutoff averaged at least 20 reads per tem-
plate to be used for TCS formation (calculated according tometh-
ods reported previously [33]). Also, this number of consensus
sequences represented a rate of conversion of starting RNA tem-
plates to TCSs of between 10% and 30%. We estimate that for
most samples, there is a 95% chance of seeingminor variants with
a 0.1 to 0.5% abundance, depending on the exact number of TCSs
obtained. Figure 1 shows the neighbor-joining trees of a subset of
TCSs from each clinical sample of bothV1/V2 (Fig. 1a) andC2/V3
(Fig. 1b) regions of the 250-nucleotide paired-end pool (100 con-
sensus sequences per sample) and the 300-nucleotide paired-end
pool (50 TCSs per library) (Fig. 1c and d). No cross-sample con-
taminationwas observed, although a linked pair of primary-infec-
tion cases was inferred (subjects P02 and P05). In addition, EPD
PCR was used to generate env gene amplicons for 16 out of 30
late-stage samples and all 6 of the early-stage samples, with an
average of 19 EPD amplicons being analyzed per sample and an
average of 3 amplicons being cloned per subject for entry analysis
of representatives of the major env sequence lineages.
Characterization ofmajor andminor lineages by coreceptor
tropism prediction.We used the G2P algorithm (11) to infer the
presence of X4 or dual-tropic viruses (which we refer to collec-
tively as X4 viruses) in these sequence populations under two lev-
els of stringency, making X4 calls for sequences with an FPR of
5% and then at the more stringent FPR cutoff of2%. Table 2
shows the numbers and percentages of X4 viruses predicted by
G2P (FPR cutoffs of 2.0% and 5.0%) in both NGS and EPD PCR
sequences. X4 viruses were detected in 24 out of 30 late-stage
subjects by using the 2% FPR cutoff and in 26 samples by using
the 5% cutoff. However, the two additional samples (samples
C12 and C19) detected by using the 5% cutoff had 1% or less of
the total TCSs with FPR scores below 5%, while the majority
of the variants in these samples had FPR scores above 5%.
Among the 24 samples predicted to have X4 variants at both
cutoff stringencies, the 5% FPR cutoff predicted more X4 vari-
ants in 17 (71%) samples than did the 2% FPR cutoff. This
analysis highlights the uncertainty of the choice of the FPR
cutoff value in using this algorithm.
The same algorithm was also used on the samples taken early
during infection. G2P with a 2% FPR score did not call any X4
variants in these six samples, while G2Pwith a 5%FPR scoremade
X4 calls in five samples but with only a small number of TCSs
(1% of the population) (Table 2). Thus, we conclude that small
changes in the FPR can give discrepant results when estimating the
relative abundance of the X4 variant population and can give dis-
crepant results when examining samples that are likely to have a
low abundance of or no X4 variants, such as early viral popula-
tions. Overall, a 5% FPR cutoff called additional X4 variants,
largely in low abundance, in approximately two-thirds of the sam-
ples taken both early and late during infection.
In the G2P algorithm, each sequence is assigned a specific FPR
value to estimate the likelihood of a sequence being from an X4
variant. We plotted all of the assigned FPR values for these se-
quences from all of these samples. This analysis showed that
groups of sequences within each subject clustered with their FPR
values, with there being a number of groups with intermediate
TABLE 1 Demographic and clinical characteristics of study subjects and







Median age (yr) (IQR) 40.5 (27.5–49)
No. (%) of male patients 6 (100)
Median most recent CD4 cell
count (cells/l) (IQR)
600 (556–617) 23 (13–41)
Median most recent HIV RNA
level (log10 copies/ml) (IQR)
4.64 (4.30–4.83) 5.2 (5.0–5.4)
Median no. of days after infection
(IQR)
328 (135–448) NA
Median no. of TCSs (IQR) 1,532 (1,332–1,883) 1,357 (992–1,982)
Median sequencing depth (%)
(IQR)b
0.2 (0.16–0.22) 0.22 (0.15–0.33)
a IQR, interquartile range; TCS, template consensus sequence; NA, not applicable.
b Sequencing depth is defined as the lowest abundance of a variant that can be detected
with a 95% chance of a certain number of TCSs.
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values andwhat appeared to be a tight clustering of lowFPR values
for those predicted to be X4 variants (Fig. 2). These results suggest
that these sequence variants represent distinct lineages with simi-
lar FPR values within the host rather than a continuum of vari-
ability.
Linkageof FPRscores andphylogenetic lineages of viral pop-
ulations basedonC2/V3 sequences. In order to examine the pop-
ulation structure of these sequences, we created neighbor-joining
trees for the sequences from each subject. In this analysis, we col-
or-coded the phylogenetic lineages with the FPR score for each
sequence, binned as 2%, 	2% and 5%, 	5% and 10%,
	10% and 20%, and 	20%. We consider values of 2% to
represent true X4 viruses, values of 	20% to be true R5 viruses,
and values between these two to be intermediate. As shown in Fig.
3 and Fig. S1 in the supplemental material, for the C2/V3 trees for
the late-stage subjects, the most stringently called X4 sequences
(2% FPR) are associated with one or more discrete lineages
within the population. In some of these samples, there are distinct
viral lineages with intermediate FPR values, with the clearest ex-
amples being samples C04, C07, C09, C20, and C25. In two sam-
ples (samples C27 and C28), almost all of the sequences have low
FPR values (below 2%). In one sample (sample C18), there are
FPR scores of between 1.7% and 16% for sequences within one
distinct viral lineage, while the remaining portion of the popula-
tion has FPR scores of 	20%. After examining the sequences of
the FPR scoremixtures in this particular lineage, we found that all
sequences in this lineage contain a V3 11K or -R mutation, a dis-
ruption in the GPGR crown (GPKR), and other changes not asso-
ciated with R5 viruses, consistent with this lineage likely being an
X4 lineage but poorly recognized by the G2P algorithm. In all
FIG 1 Neighbor-joining trees for a pool of 100 (250-bp pool) or 50 (300-bp pool) randomly picked consensus sequences from each sample at both the V1/V2
and C2/V3 regions. P01 to P06 are six samples obtained from subjects early during infection. C01 to C30 are 30 samples from late-stage HIV-1-infected subjects.
The bar for the phylogenetic trees indicates the number of nucleotide substitutions per site. (a) V1/V2 tree of the 250-bp sequencing pool. (b) C2/V3 trees of the
250-bp sequencing pool. (c) V1/V2 tree of the 300-bp sequencing pool. (d) C2/V3 trees of the 300-bp sequencing pool.
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other cases, the X4 lineages with a 2% FPR were relatively ho-
mogeneous in their FPR scores, and these lineages coexisted with
other,most often relatively homogeneous, lineages with a range of
FPR values usually strongly predicted to be R5, with FPR values of
	20%. Thus, another feature of viral populations that carry
strongly called X4 viruses is that these sequences represent a dis-
tinct lineage within the sequence population.
Overall, we detected clear X4 lineages in 80%of these late-stage
subjects (24 of 30). This frequency of X4 variants within people
infected with subtype B HIV-1 is higher than previously reported
estimates of around 50% (4). The fraction of the viral population
in the X4 lineage within each person varied widely, ranging from
3% to 85%. Our ability to detect X4 variants at a higher level may
be due to the use of NGS, as about half of the subjects with X4
viruses had a viral population where the X4 lineage comprised
20%of the total viral population. It is important to note that the
use of Primer ID is essential in validating the number of genomes
queried in this analysis to ensure that our assignment of lineage
abundance is well above our subject-specific measured depth of
sampling (i.e., the number of TCSs).
The remaining samples had no strong X4 lineages, including
samples C01, C02, C12, C19, C23, and C29 from the late-stage
subjects and samples P01 to P06, representing all of the early-stage
subjects. However, the lineages within these viral populations in
these subjects varied in their FPR values: samples C01, C02, C23,
C29, and P03 had strongly R5 lineages; samples C19, P01, P02,
P05, and P06 had relatively homogeneous populations with inter-
mediate FPR scores; sample P04 had a mixture of lineages with
intermediate FPR scores and R5 FPR scores, while the tree topol-
ogy is relatively condensed; and sample C12 had two distant lin-
eages, onewith an FPR score above 20%and the otherwith an FPR
score of around 6%. Based on data from the genotypic analysis
alone, it is difficult to assess the significance of the lineages with
intermediate FPR scores with respect to their contribution to an
X4phenotype, especially given that strongX4 calls were easily seen
as discrete lineages.
TABLE 2 Numbers and percentages of X4 variants predicted by using the Geno2pheno[CORECEPTOR] algorithm on sequences assessed by both NGS
and SGA
Sample
No. of C2/V3 sequences No. (%) of X4 variants predicted by Geno2pheno[CORECEPTOR]
NGSa SGA
FPR of2.0% FPR of5.0%
NGS SGA NGS SGA
C01 1,116 20 0 0 0 0
C02 381 17 0 0 0 0
C03 1,031 23 154 (15) 1 (4) 155 (15) 1 (4)
C04 502 15 102 (20) 2 (13) 424 (85) 12 (87)
C05 1,438 17 670 (47) 8 (47) 672 (47) 8 (47)
C06 616 29 170 (28) 12 (41) 170 (28) 12 (41)
C07 1,248 19 152 (12) 4 (21) 962 (77) 17 (89)
C08 1,610 38 217 (13) 3 (8) 217 (13) 3 (8)
C09 2,108 38 401 (19) 3(8) 579 (28) 6 (16)
C10 808 24 66 (8) 10 (42) 66 (8) 10 (42)
C11 900 266 (30) 267(30)
C12 1,353 14 0 0 13 (1) 0
C13 2,230 200 (9) 201 (9)
C14 2,334 523 (22) 524 (22)
C15 988 178 (18) 178 (18)
C16 855 36 657 (77) 28 (78) 670 (78) 28 (78)
C17 635 111 (17) 111 (17)
C18 1,361 74 (5) 164 (12)
C19 787 0 2 (0.3)
C20 2,626 154 (6) 161 (6)
C21 1,141 12 30 (3) 0 1,102 (97) 8 (67)
C22 1,418 203 (14) 207 (15)
C23 1,247 0 0
C24 2,019 92 (5) 92 (5)
C25 1,431 18 228 (16) 2 (11) 1,381 (17) 2 (11)
C26 2,166 333 (15) 336 (16)
C27 1,791 19 304 (5) 1 (5) 1,790 (100) 19 (100)
C28 1,868 19 1,585 (85) 17 (89) 1,869 (100) 19 (100)
C29 2,856 0 0
C30 3,103 841 (27) 841 (27)
P01 2,732 19 0 0 8 (0.1) 0
P02 1,464 17 0 0 4 (0.3) 0
P03 1,963 20 0 0 0 0
P04 669 11 0 0 1 (0.1) 0
P05 1,552 9 0 0 4 (0.3) 0
P06 1,277 10 0 0 2 (0.2) 0
a Number of template consensus sequences.
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Another layer of complexity in interpreting the genotypic calls
for the entire population was the presence of one or two sequence
variants with more X4-like FPR scores embedded within a lineage
with a higher FPR score. For example, a majority of the sequences
in samples P01, P02, and P05 had intermediate FPR scores of
between 5% and 20%.However, a total of 7 distinct sequences had
stronger X4 calls (FPR of 2 to 5%). None of these sequences
formed a distinct lineage. Only one nucleotide substitution distin-
guished these sequences within each lineage, and none of them
had an amino acid substitution typically associated with X4 vi-
ruses. Sample C07 had 3 major lineages with distinct FPR values
that are labeled in red (2%), orange (2 to 5%), and green
(	20%) in Fig. 3. Several sequences with FPR scores of2%were
found in the lineage with the intermediate FPR value. However,
these sequences had just one nucleotide difference from the lin-
eage consensus sequence and did not themselves form a discrete
lineage. Thus, we conclude that the strongest X4 calls (2% FPR)
are associated with discrete lineages of sequences within the pop-
ulation and that weaker X4 calls either identify lineages with in-
termediate values or represent occasional sequence variants inter-
mingled with lineages with stronger R5 calls. The appearance of a
single X4-like sequence variant differing by a single nucleotide
from the consensus sequence of the lineage could be the result of a
residual sequencing error, which should represent a total of about
25 single nucleotide polymorphisms introduced into a data set of
1,000 C2/V3 sequences based on an error rate of 1 in 10,000 nu-
cleotides sequenced (33).
Entry phenotype associated with major lineages. In an effort
to link the X4, intermediate, and R5 FPR scores with the pheno-
type of specific lineages, we created full-length env gene expression
vectors for the major lineages within these subjects. We first used
EPD PCR to create a series of amplicons for sequencing and com-
parison to the lineages identified by using the C2/V3 MiSeq-gen-
erated sequences. The number of amplicons sequenced for each
sample and the genotypic predictions are shown in Table 2. Given
the comparatively low number of genomes analyzed by this
method (20 per sample), we would not expect the percentage of
X4 variants to recapitulate the percentage of X4 variants identified
by the much larger sample size of sequences obtained by deep
sequencing. However, we were interested in identifying variants
from each of the major C2/V3 lineages. Amplicons were selected
based on sequence similarity to the major C2/V3 sequence lin-
eages, and env expression clones were generated.
The env clones were used to generate pseudotyped viruses with
FIG 2 Distribution of Geno2pheno[CORECEPTOR] false-positive rates among viral populations. P01 to P06 are six samples from subjects early during infection.
C01 to C30 are 30 samples from late-stage HIV-1-infected subjects.
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the expressed Env protein on the virion generated by coexpression
with an env deletion genome that contained a reporter gene (lu-
ciferase) that was used to identify subsequent infectious events.
Using Affinofile cells, we were able to test the entry phenotype
predicted by the genotype by testing individually isolated env
genes from the same samples that represented the major lineages
identified by NGS. Affinofile cells have inducible CCR5 and CD4
but constitutively express CXCR4. Maraviroc and AMD3100, co-
receptor inhibitors for R5 and X4 viruses, respectively, were used
under the following three conditions to discern between CCR5-
FIG 3 Phylogenetic trees of the C2/V3 region for study samples showing different Geno2pheno[CORECEPTOR] FPRs among viral populations. Brown arrows
indicate the identical or closest sequences in the tree of clones that we obtained by single-genome amplification and that were examined for entry phenotypes in
vitro. Clone names and their phenotypic tropism (R, R5; X, X4; D, dual tropism) are indicted along with the arrows. The bar in the phylogenetic trees indicates
the number of nucleotide substitutions per site.
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tropic, CXCR4-tropic, and dual-tropic viruses: (i) maraviroc
only, (ii) AMD3100 only, or (iii) maraviroc plus AMD3100. Table
3 summarizes the phenotypic testing results as well as FPR scores
for each clone. In Fig. 3, the brown arrows indicate the C2/V3
lineage with the sequence most similar to that of the clone. Clone
names and their phenotypic tropisms are also labeled along with
the brown arrows. In total, we tested 4 control env genes and 49
new env genes in these experiments, where 15 env clones encoded
Env proteins that showed dual tropism, 3 encoded Env proteins
that showed CXCR4 tropism, and 31 encoded Env proteins that
showed CCR5 tropism. All of the 14 env clones with FPR scores of
2% encoded Env proteins that were X4 or dual-tropic viruses,
consistent with the reliability of an inference of CXCR4 tropism
associated with a low FPR score. All of the 13 env clones with FPR
scores of 	20% encoded Env proteins that were CCR5 tropic,
consistent with the 20% cutoff being a reliable call for R5 viruses.
In addition, no env clones from the early-stage subjects encoded
Env proteins that were X4 variants.
We next explored the env clones with intermediate FPR
scores in an attempt to clarify the determinants of CXCR4 tro-
pism in the X4 viruses with intermediate FPR scores. There
were 22 viral env gene clones with FPR values that were spread
between 2.1 and 20%; of these, 4 encoded Env proteins that
were X4/dual tropic (the rest were CCR5 tropic), and all 4 of
these clones had FPR values of 6% (as did 5 other R5 env
clones). All of the 11 clones with FPR scores of between 6% and
20% encoded Env proteins that were CCR5-only viruses. We
then inspected the V3 sequences associated with intermediate
FPR scores (n  22 clones). Figure 4 shows the V3 loop se-
quences of these intermediate clones as well as their FPR scores
and phenotypes. While the data set is too small to allow statis-
tical analysis, inspection of the sequences suggests several paths
to consider concerning how to predict a phenotype from these
intermediate genotypic scores/sequences. In general, sequences with
intermediate values frequently have added basic amino acid
substitutions, but these substitutions alone do not explain the
pattern of measured phenotypes. Thus, it is useful to think of
other key sites as potentially enabling the phenotypic expres-
sion of the basic substitutions, with these enabling mutations
either being linked to the X4 phenotype or at least being a
polymorphism that is compatible with the X4 phenotype. At
one extreme, subject C04 had several clones that contained a
25R substitution and a low FPR score (3.0%) but were R5
viruses based on their phenotype. Since 25R can appear in both
R5 and X4 viruses, there must be additional determinants
needed to realize the X4 phenotype. In this subject, both posi-
tions 20 and 21 were mutated to aliphatic amino acids in the
cocirculating X4 viruses, in addition to other X4-related sub-
stitutions, suggesting that these positions may regulate the ex-
pression of the X4 phenotype for basic substitutions in some
cases. While this analysis is very exploratory, among all 13 exam-
ples with intermediate FPR values of between 2 and 6%, X4 vari-
ants met the following criteria: the presence of one or more basic
amino substitutions at positions 13, 23, 24, 25, and 32 (in addition
to position 11) and the substitution of an aliphatic amino acid at
either position 20 or 21 (and, based on skewing in X4 populations,
perhaps including position 19), whereas the R5 variants with in-
termediate FPR scores did not meet these criteria.
Comparison of G2P FPR scores of transmitted/founder vi-
ruses and late-stage viral lineages.Most of our late-stage samples
contained one ormore X4 viral lineages. In contrast, the transmit-
ted/founder (T/F) viruses are typically R5 viruses (3). We were
interested in the possibility that the lineages with intermediate
FPR scores in late-stage subjects are skewed toward the X4 popu-
lation or in determining whether they represent a normal distri-
bution of R5 lineages. In order to compare the predicted corecep-
tor usage/FPR scores of founder viruses and late-stage viral
lineages, we downloaded aligned sequences from 104 acutely in-
fected subjects, as described previously by Keele et al. (3). The
consensus sequence was used to represent each T/F virus, and an
FPR score was determined for each V3 sequence. For comparison,
all viral lineages with abundances of	1% in the deep-sequencing
analysis were used from the viral population from the late-stage
subjects. A total of 153 lineages were identified from the 30 late-
stage samples (Fig. 5A). The FPR scores for all of these lineages
from the late-stage subjects were significantly lower (Fig. 5A) than
those for T/F viruses (Fig. 5C). However, the range of FPR scores
of the single major lineage in each subject sample (Fig. 5B) was
comparable with that of the T/F viruses (Fig. 5C). When we ex-
cluded theX4 lineages from the late-stage subjects with FPR scores
of2%, the FPR scores of the remaining late-stage viral lineages
(Fig. 5D) or the single major lineage from each subject (Fig. 5E)
were comparable to the FPR scores of the T/F viruses, regardless of
whether we included all of the T/F viral sequences (Fig. 5C) or
excluded the fewT/F viral sequenceswith FPR values of2% (Fig.
5F). We further separated the late-stage viral lineages with FPR
scores of 	2% into those from R5-only samples (Fig. 5G) and
those from mixed R5/X4 samples (Fig. 5H). The distributions of
FPR scores of R5 lineages (FPR score of2%) in the samples that
also had an X4 lineage (Fig. 5H) were similar to those of the
founder viruses (Fig. 5F). The distribution of FPR scores in the R5-
only samples (Fig. 5G) also did not differ significantly from the
distribution of FPR scores in the samples with X4 lineages when
the lineages with FPR scores of 2% were excluded (Fig. 5H).
Overall, we conclude that the distribution of FPR scores for the
lineages with scores of	2% are similar between samples that have
an X4 viral lineage (FPR score of 2%) and those that do not,
regardless of whether the virus is isolated early or late during in-
fection. This observation reinforces the ideas that the X4 lineages
represent a specific clade within the viral population and that
there is not a general shift towardX4-like sequences, as assessed by
the FPR score, in subjects who evolve an X4 lineage.
Restricted recombination between specific lineages within
the viral population. There are conflicting data as to whether X4
and R5 viruses replicate in the same cell type or in distinct cell
types. One way in which to identify replication in the same cell
type would be through the detection of recombinants, indicating
infection by X4 and R5 viruses in the same cell, a prerequisite for
the formation of heterodimeric genomic RNAs that are the basis
for recombination during a subsequent round of infection. To
address this question, we examined the linkage between theV1/V2
lineages from the deep-sequencing analysis and the C2/V3 lin-
eages. Specifically, we determined if there were V1/V2 lineages
that were shared among different C2/V3 lineages, indicative of
recombination, or if there were discrete V1/V2 lineages that were
linked to specific C2/V3 lineages, indicative of genetic isolation. In
a control experiment, we constructed Primer ID sequencing li-
braries from mixed viral RNAs from two endpoint dilutions of a
viral outgrowth assay mixture using same template copy number
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TABLE 3 Phenotyping of 4 env controls and 49 env isolates from 19 samples
Sample Clone FPR (%)
Infectivity vs that for no-drug control (%)
Phenotype DescriptionMaraviroc AMD3100 AMD3100maraviroc
BAL NA 24.7 0.18 66.18 0.11 R5 Control
JR-CSF NA 31.7 1.73 92.57 0.28 R5 Control
BV-5002 NA 2.0 145.64 0.80 0.03 X4 Control
NL43 NA 2.0 145.36 0.10 0.13 X4 Control
C01 B7 56.5 0.81 159.62 1.26 R5
D11 42.7 0.35 177.87 0.47 R5
C02 A10 38.0 0.80 84.05 0.55 R5
F9 38.0 0.18 62.28 0.17 R5
C03 D11 68.6 0.20 75.55 0.22 R5
E8 68.6 0.05 61.10 0.05 R5
C04 D11 2.6 0.31 141.78 0.68 R5
F4 2.9 0.08 63.45 0.12 R5
G1 2.7 0.08 103.96 0.24 R5
G10 6.9 0.77 91.48 0.30 R5
G2 0.7 84.34 39.04 0.40 Dual
C05 C4 64.0 0.22 103.64 0.17 R5
E4 1.7 94.55 67.94 27.44 Dual
C06 A7 21.8 18.62 122.43 27.50 R5
D1 24.7 16.40 76.27 6.81 R5
D10 24.7 15.43 96.58 9.94 R5
E6 0.5 88.37 64.79 39.04 Dual
C07 C11 1.7 102.89 42.17 3.19 Dual
C8 5.0 1.58 123.26 0.56 R5
F5 5.0 0.77 124.26 0.17 R5
C08 F9 0.5 88.57 0.06 0.10 X4
H12 0.5 158.23 3.70 0.17 X4
C09 A4 1.1 123.05 50.92 0.42 Dual
D1 4.8 4.66 57.93 0.28 Dual
E6 4.8 23.60 38.31 0.12 Dual
G5 11.4 1.34 75.12 0.87 R5
C10 D9 0.0 133.23 1.39 1.58 X4
G4 67.5 3.51 79.59 2.15 R5
C12 D9 5.3 99.92 39.14 6.00 Dual
E4 5.3 99.09 67.85 1.48 Dual
F8 43.2 0.41 97.86 0.06 R5
C16 D10 1.7 52.21 37.72 0.17 Dual
B7 16.6 0.08 104.19 0.05 R5
C21 B1 5.0 0.08 104.19 0.05 R5
B3 4.0 0.18 62.81 0.14 R5
C25 B2 0.2 98.79 56.84 0.23 Dual
D1 5.0 0.05 96.29 0.08 R5
E12 5.0 0.07 95.85 0.44 R5
(Continued on following page)
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for each virus. These two endpoint dilutions had been sequenced
separately and had 9 nucleotide differences in the V1-through-V3
region. After mixing, downstream steps of PCR amplification and
sequence analysis were carried out. We found that recombinants
between the two different samples had formed but only at a low
level (0.1%) (S. K. Lee, S. Zhou, P. L. Baldoni, E. Spielvogel,
N.M. Archin,M.G.Hudgens, D.M.Margolis, and R. Swanstrom,
submitted for publication). While more recombinants were likely
present after the PCR step, the construction of a TCS for each
template obscures their presence, since they would rarely become
the majority sequence for that template.
Figure 6 shows the neighbor-joining trees of the V1/V2 region
and the C2/V3 region for four samples. X4 and R5 viral lineages
are indicated, and the different V1/V2 lineages are color-coded. In
sample C03 (Fig. 6A), there is a distinct lineage in the V1/V2 tree
(V1/V2 lineage D [V1V2-D]) linked to the X4 C2/V3 lineage, and
the three other V1/V2 lineages form the major R5 lineage in the
C2/V3 tree. Thus, recombination between the X4 and R5 viruses
between V1 and V3 was extremely rare, while different R5 V3
lineages were linked with several different V1/V2 lineages, consis-
tent with recombination. Sample C05 (Fig. 6B) had seven distinct
V1/V2 lineages (lineages A to G), three of which were associated
with the major R5 V3 lineage (lineages V1V2-A, -B, and -C with
C2/V3 R5 lineage 1) and four of which were associated with the
twoX4 virus lineages (lineagesV1V2-D, -E, -F, and -GwithC2/V3
X4 lineages 2 and 3); there appeared to be extensive mixing/re-
combination between the two C2/V3 X4 lineages and their V1/V2
lineages but very little mixing/recombination between the X4 lin-
eages and the R5 lineage. In sample C10 (Fig. 6C), there were four
major V1/V2 lineages, and each onewas strongly associated with a
separate C2/V3 lineage, three of which were R5 and one of which
was X4. In this case, all four lineages appeared to be replicating
independently without mixing through recombination. Linked
G2P V3 scores were used to color-code the V1/V2 trees for all
TABLE 3 (Continued)
Sample Clone FPR (%)
Infectivity vs that for no-drug control (%)
Phenotype DescriptionMaraviroc AMD3100 AMD3100maraviroc
C27 D1 0.2 80.77 57.49 0.30 Dual
F4 1.8 22.37 92.32 0.50 Dual
C28 D9 1.7 62.16 33.30 0.37 Dual
F3 1.9 76.52 71.27 0.70 Dual
P04 B6 6.0 0.12 89.75 0.08 R5
E12 41.2 3.03 85.81 2.64 R5
G6 10.2 2.03 83.84 1.94 R5
P05 A10 7.0 6.52 88.10 7.46 R5
B8 7.0 4.48 86.71 4.70 R5
P06 D10 16.9 0.26 62.59 0.28 R5
D12 16.9 0.35 92.78 0.25 R5
FIG 4 V3 amino acid (aa) sequences of cloned env sequences with intermediate FPRs and their coreceptor phenotypes.
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remaining samples with mixed R5 and X4 populations, and these
trees are shown in Fig. S2 in the supplemental material. In sum-
mary, all X4 lineages with FPRs of2%have little to no detectable
recombination with R5 lineages within X4-containing samples.
In one early-stage sample, sample P04 (Fig. 6D), all of the se-
quences suggested R5 viruses, but there were a number of C2/V3
lineages based on distinct polymorphisms. Conversely, there were
multiple distinct V1/V2 lineages (labeled in different colors in Fig.
6D). When these patterns were combined, it was clear that there
were some C2/V3 lineages (lineages 1 and 3) that had sampled
most (but not all) of the V1/V2 lineages, someC2/V3 lineages that
had relatively few recombinants (lineages 2, 4, and 5), and one
C2/V3 lineage largely composed of a linkage to just two V1/V2
lineages (C2/V3 lineage 6). These patterns suggest several stages of
population mixing and isolation coexisting within this infected
person.
DISCUSSION
We have used two approaches to analyze viral sequence popula-
tions that have not previously been applied to the examination of
HIV-1 populations late in the disease course. The traditional use
of PCR results in the introduction of PCR-mediated recombina-
tion (18), which can disrupt linkages within the population, con-
founding the analysis of phylogenetic relationships. PCR itself in-
cludesmisincorporation, andNGS platforms suffer from both the
problem of requiring a prior PCR step and having a relatively high
rate of errors in the sequence data set. By using endpoint dilution
PCR to generate full-length env genes and Primer IDNGS to sam-
ple the viral population in depth, we have been able to characterize
these late-stage viral populations in the absence of these con-
founding technical artifacts. Using these approaches, we have
found that most stringently called X4 variants are usually clus-
tered in distinct lineages, that conventional prediction algorithms
have difficulties in predicting X4 variants with intermediate
scores, and that there is limited recombination betweenX4 andR5
variants.
Most current approaches using NGS to study HIV-1 popula-
tions have serious limitations in accurately sampling the popula-
tion. First, most approaches usually require a preceding PCR
amplification step. Thus, PCR errors, including nucleotidemisin-
corporation by the polymerase, PCR recombination, and PCR
resampling, may alter diversity as well as skew the allelic frequen-
FIG 5 Comparison of Gene2pheno[CORECEPTOR] FPRs of the founder virus and lineages from late-stage clinical samples.
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cies (29, 30). Second, in some approaches, the amplicons are first
sheared before sequencing, and the sequencing reads are aligned
with a reference sequence (41).With this approach, it is difficult to
perform linkage analysis and estimate allelic frequencies. Third,
sequencing errors can also introduce artificial diversity into the
population. For instance, 454 pyrosequencingwas broadly used in
coreceptor tropism deep-sequencing studies, but it suffers from
severe homopolymer errors, while the homopolymer issue is not a
feature of the MiSeq platform used in this study (42, 43); further-
more, the homopolymer problem is a feature of all platforms that
allow multiple or continuous additions of nucleotides where the
number of additions in a homopolymer region must be inter-
preted by downstream software analysis. In addition, some studies
use a reference sequence in their bioinformatics pipelines to com-
plement the false insertions and deletions due to the homopoly-
mer errors. This approach can be problematic when processing
sequencing data from highly variable regions such as the V3 loop
of the HIV-1 env gene, as it may create artificial alleles.
FIG 6 Lineages of the V1/V2 region and the C2/V3 region and their recombination in 4 subjects (subjects C03, C05, C10, and P04). For samples from subjects
C03, C05, and C10, lineages have the same color-codes in the V1/V2 trees and the pie charts of the major lineages of the corresponding C2/V3 trees, while the
C2/V3 trees are color-coded for coreceptor tropism (red for X4 and green for R5 variants). The percentages on the pie charts show the abundances of the V1/V2
lineages in the C2/V3 lineages. In subject P04, as all variants are R5 variants, lineages have the same color-codes in the corresponding V1/V2 and C2/V3 trees. (a)
Subject C03; (b) subject C05; (c) subject C10; (d) subject P04.
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The Primer ID sequencing approach coupled with the
MiSeq platform overcomes these serious limitations of conven-
tional deep sequencing of genetically diverse viral populations
by addressing the sampling depth, greatly reducing the se-
quencing error rate, and largely removing PCR-mediated re-
combination artifacts. This allowed us to perform a phyloge-
netic analysis where one TCS corresponds to one original viral
template/genome, thus validating the level of viral population
sampling for each patient sample analyzed. EDP PCR accom-
plishes these same features of characterizing viral populations
and has the advantage of permitting the generation of longer
amplicons (such as intact env genes) but has the limitation of a
modest sampling depth compared to what is easily achieved by
using next-generation sequencing. We took advantage of the
strengths of these two approaches to examine X4 populations
that evolve late in the HIV-1 disease course.
The most widely used entry-phenotype-predicting algo-
rithm is Geno2Pheno[CORECEPTOR], which ascribes a false-pos-
itive rate value to a given V3 sequence to determine the prob-
ability of that sequence being from an X4 or dual-tropic virus
based on an analysis of a large data set of viruses that were both
sequenced and phenotyped (6). The MOTIVATE clinical trial
showed that an FPR below 2% was strongly associated with
treatment failure when the CCR5 inhibitor maraviroc was in-
cluded in a multidrug regimen, and FPR values of between 2
and 5.75% were associated with a loss of antiviral activity of
this inhibitor. Based on data from these trials, some guidelines
suggest the use of an FPR value of 5.75% to predict X4/dual-
tropic viruses or, even more conservatively, a 20% FPR cutoff.
It seems clear that assignment of an X4 phenotype to a se-
quence with an FPR value of2% has a very high probability of
being correct (all 14 clones tested from 12 subjects in our data
set were X4/dual tropic when the FPR value was 2%), and a
similar argument can be made for an R5 phenotype when the
FPR value is 	20% (all 13 clones tested from 8 subjects in our
data set were R5 when the FPR value was	20%). However, we
were also interested in determining if detailed information
about the population structure could add information about
the sequences with FPR values of between 2% and 20%, where
4 of the 22 clones tested from 10 subjects were X4/dual tropic.
Focusing just on lineages with FPR values of 2%, we found
such lineages in 80% of this study population of subjects with
late-stage disease, a value higher than what was previously seen,
suggesting that next-generation sequencing can increase the
sensitivity of detection of these variants.
We used several approaches to gain a better understanding of
the meaning of variants with intermediate FPR values (between
2% and 20%). Overall, we observed that the distribution of FPR
values of HIV-1 variants in individual subjects was not continu-
ous; among late-stage subjects, the FPR values were similar within
specific sequence lineages and could differ significantly between
lineages within the same subject. Sequences with an FPR of2%
were usually, but not always, clustered in a single distinct lineage.
We attempted to determine if there was additional information
about the presence of X4 viruses with FPR values above 2% in
these subjects. However, the distribution of variants with FPR
values above 2% in subjects withX4 viruses (i.e., with FPR lineages
of2%) was not distinguishable from either a panel of transmit-
ted/founder viruses or the lineages present in late-stage subjects
who did not have an X4 lineage (defined as an FPR of 2%)
(Fig. 2 and 5). We did not see evidence of a genotypic history of a
gradual shift in FPR values resulting in the strong X4 lineage,
suggesting that these viruses do not grow out to be an appreciable
fraction of the population until they have a strong X4 signal. This
conclusion is limited due to the fact this is a cross-sectional anal-
ysis of late-stage subjects, although in half of the subjects with X4
variants, this lineage represented20% of the population, rang-
ing down to 3%.
We also examined the V3 sequences themselves to see if there
were clues that might distinguish between X4 and R5 variants
within the FPR range of 2% to 20% in our data set. The premise
was that theG2P databasemay be incomplete in its ability to assess
rare V3 sequences, while other algorithms could be designed to
compensate for this limitation. We also note that there were three
env gene clones (from subjects C05 and C06) whose encoded pro-
teins retained some infectivity in the presence of both the CCR5
and CXCR4 inhibitors. It was reported previously that CCR5-
tropic but maraviroc-resistant variants can use inhibitor-bound
CCR5 (44). The three env clones from this study may encode Env
proteins that are examples of a naturally occurring CCR5-tropic
maraviroc-resistant virus, or they may use coreceptors other than
CCR5 or CXCR4.
Given a deep-sequencing view of the V3 sequence popula-
tion, we propose the following steps for interpretation of the
data. First, a clear lineage of sequences with FPR values of2%
are scored as X4/dual-tropic variants. We also propose that
spurious or isolated sequences within an otherwise homoge-
neous FPR lineage should be interpreted as the bulk of the
lineage rather than as isolated FPR values of single sequences,
which could still be impacted by rare sequencing errors; thus,
FPR assignments should be made for distinct lineages, which
brings attention to the necessity of documenting the depth of
sampling by using an approach like Primer ID. Conversely,
lineages with an FPR of 	20% should be uniformly treated as
R5 lineages. This leaves the question of how to interpret lin-
eages with FPR values of between 2% and 20%. We found one
case where the entire lineage was of mixed FPR values, where
inspection of the V3 sequences clearly suggested that this was
an X4 lineage (with 11K and -R variants). Examination of the
more homogeneous lineages of V3 sequences with FPR values
of between 2% and 20% provided hints about how to improve
the R5/X4 calls in this ambiguous region. Specifically, observ-
ing the presence or absence of basic amino acid substitutions at
positions 11,13, 23, 24, 25, and 32 with an aliphatic amino acid
(V or I) at position 20 or 21 correctly called 18 phenotyped
clones with these in-between FPR values (	2% and 20%).
The use of EDP PCR for generating our amplicons for cloning
ensured no fortuitous recombination in the construction of the
clones, but this requirement limits the number of phenotyped
clones available to extend this initial correlation. The use of
site-directed mutagenesis could provide some support for this
suggestion, although the role of background mutations in de-
fining the evolutionary pathways for V3 is poorly understood.
Several previously reported studies used deep sequencing to
predict HIV-1 coreceptor usage by sequencing of the HIV-1 env
V3 region (26, 45–48).Most of those studies used 454 sequencing,
which was limited by homopolymer errors and relative low
throughput compared to the Illumina or IonTorrent platform
(25). In these studies, the presence of X4 variants was defined by
the detection of	2% of sequences with FPR values of3.5% in
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the viral population, as seen in the MERIT and MOTIVATE co-
hort studies (12, 13, 49). However, the predetermined FPR is ar-
bitrary, and our data show that an FPR of between 2% to 6% can
indicate either X4 or R5 variants.Meanwhile, without defining the
sampling depth and correcting PCR resampling, the percentage of
X4 variants detected is the percentage of X4 sequences in the PCR
amplicon instead of the abundance of X4 variants among the viral
genomes. Thus, the 2% cutoff in the viral population is also arbi-
trary and inaccurate, since there is no knowledge of how many
templates/genomes were sampled. Several studies claimed that 10
to 20% of viruses from primary infection or transmitted viruses
could be X4 variants by deep sequencing of the V3 loop (45, 48).
We believe that these conclusions are compromised by the flawed
sequencing methods and bioinformatics determination of X4
variants, and a more accurate approach, such as Primer ID se-
quencing coupled with phylogenetic analysis, should be used for
such types of studies.
Each viral particle contains two copies of the viral genome.
Typically, the two copies of the genome are identical, being
transcribed from the same provirus. When multiple viruses
infect the same host cell, virions containing two different ge-
nomes can be produced. When these heterodimeric viruses in-
fect target cells, reverse transcriptase can switch back and forth
between the two templates during DNA synthesis; thus, recom-
binant viruses can be produced (50). Recombination plays an
important role in viral evolution (51). In this study, we found
that the X4 and R5 variants in the same host displayed limited
evidence of recombination between these variants. All X4 and
R5 variants had distinct V1/V2 and C2/V3 regions. In contrast,
in individuals with multiple X4 lineages or R5 lineages, we
observed extensive recombination within X4 or R5 variants.
This observation suggests that R5 and X4 variants are compart-
mentalized in different host cell types, or alternatively, their
recombinants have low fitness and do not grow out in the viral
population. Several previous studies have shown that X4 vari-
ants preferentially infect naive T cells and that R5 variants pref-
erentially infect memory T cells (52–54). However, one study
observed that the level of integration is lower in resting naive T
cells than in memory T cells regardless of the coreceptor tro-
pisms within the viral population (55).
In conclusion, Primer ID deep sequencing provides a novel
approach to study genetic structures of viral populations. X4 vari-
ants may be more prevalent than previously reported when as-
sessed by using NGS and with a sufficient depth of sampling. Phy-
logenetic analysis to identify lineages of sequences with low FPR
valuesmay provide additional information for accurately predict-
ing X4 variants by using V3 sequences. Limited recombination
occurs between X4 and R5 lineages, suggesting that X4 and R5
variants are genetically isolated andmay be replicating in different
cell types.
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